Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)

• मुख्य लेखकों: Paolo Gisondi (लेखक), Alice B. Gottlieb (लेखक), Boni Elewski (लेखक), Matthias Augustin (लेखक), Sandy McBride (लेखक), Tsen-Fang Tsai (लेखक), Christine de la Loge (लेखक), Frederik Fierens (लेखक), José M. López Pinto (लेखक), Nicola Tilt (लेखक), Mark Lebwohl (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Adis, Springer Healthcare, 2022-12-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Abstract Introduction Certolizumab pegol (CZP) is an Fc-free, PEGylated, anti-tumour necrosis factor biologic. Safety and efficacy data for CZP over 3 years have been previously reported. We report 3-year quality of life (QoL) outcomes for patients treated with CZP, pooled from two phase 3 trials. M...